The drugmaker once employed 160 people and was named a finalist for Florida Manufacturer of the Year by the state’s manufacturing association in 2016.
In September 2019, KRS Global issued a voluntary recall of all lots of its unexpired human and animal drugs due to lack of sterility assurance. In 2015, the drugmaker received a warning letter from the FDA for failing to monitor the air conditioner in its clean room daily. That failure could pose a contamination risk, the FDA said.
KRS Global had laid off 60 workers as of last November, citing “unforeseen business circumstances outside the company’s control which have caused a significant downturn in business,” according to the Sun Sentinel.
In its bankruptcy filing, the drugmaker claimed less than $50,000 in assets and up to $50 million in liabilities.
Read the full article here.
More articles on pharmacy:
CVS to add 600 HealthHUBs, link them to lower Aetna copays
Civica Rx calls on generic drugmakers to donate to its cause
Pfizer, GlaxoSmithKline give timeline for IPO of joint venture
